10 results match your criteria: "Health Sciences Center T16[Affiliation]"
J Invasive Cardiol
July 2020
Transcatheter Aortic Valve Replacement Program, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794-8160 USA.
This case illustrates that transfemoral transcatheter aortic valve replacement is safe and feasible in patients with bicuspid aortic stenosis with extremely large annulus and concomitant severe left ventricular dysfunction.
View Article and Find Full Text PDFJ Invasive Cardiol
August 2020
Department of Medicine, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794 USA. puja.parikh@ stonybrookmedicine.edu.
Background: Observational data suggest that early- and long-term outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) differ significantly between men and women, but have demonstrated conflicting results. This study sought to examine early- and long-term mortality with TAVR and SAVR in women versus men.
Methods: Electronic search was performed until February 2018 for studies reporting sex-specific mortality following TAVR or isolated SAVR.
J Invasive Cardiol
January 2020
Division of Cardiology, Stony Brook University Medical Center, Health Sciences Center T16, Room 080, Stony Brook, NY 11794-8160 USA.
Background: The association between chronic kidney disease (CKD) and outcomes following transcatheter aortic valve replacement (TAVR) in the setting of newer-generation transcatheter heart valves (THVs) is not well known. Accordingly, we sought to assess the impact of CKD severity on outcomes in adults undergoing TAVR with newer-generation THVs.
Methods: The study population included 298 consecutive patients who underwent TAVR with a newer-generation THV (Sapien 3 [Edwards Lifesciences] or CoreValve Evolut R or Evolut Pro [Medtronic]) from December 2015 to June 2018 at an academic tertiary medical center.
J Invasive Cardiol
October 2019
Transcatheter Aortic Valve Replacement Program, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794-8160 USA.
Transcatheter tricuspid valve-in-valve replacement via right internal jugular is safe and feasible for failed bioprosthetic valve implantation. Challenging aspects include stiff wire advancement into the pulmonary artery for rail establishment and multiple push-pull manipulations for balloon and valve advancement.
View Article and Find Full Text PDFCurr Cardiol Rep
June 2018
Division of Cardiovascular Medicine, Department of Medicine, State University of New York, Stony Brook, NY, USA.
Purpose Of Review: This review provides updates in gender disparities in the symptom profile, risk factors, quality and timeliness of guideline-based medical care, and clinical outcomes, including mortality, bleeding, and vascular complications, in patients with acute myocardial infarction (AMI).
Recent Findings: While AMI continues to be a leading cause of mortality in both men and women, significant gender differences exist in presentation, management, and outcomes. Women with AMI are older, suffer atypical symptoms, and more often present with HF and cardiogenic shock.
J Invasive Cardiol
January 2018
Transcatheter Aortic Valve Replacement Program, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794-8160 USA.
A 78-year-old man presented with severe symptomatic aortic stenosis and a heavily calcified, stenotic aortic valve. Given multiple comorbidities, the heart team agreed on a transcatheter approach via the left common carotid artery.
View Article and Find Full Text PDFArch Intern Med
February 2012
Division of Cardiovascular Medicine, Department of Medicine, State University of New York-Stony Brook School of Medicine, Health Sciences Center T16-080, Stony Brook, NY 11794.
Background: Prior meta-analyses have yielded conflicting results regarding the outcomes of treatment of stable coronary artery disease (CAD) with initial percutaneous coronary intervention (PCI) vs medical therapy. However, most of the studies in prior systematic reviews used balloon angioplasty as well as medical therapies that do not reflect current interventional or medical practices. We therefore performed a meta-analysis of all randomized clinical trials comparing initial coronary stent implantation with medical therapy to determine the effect on death, nonfatal myocardial infarction (MI), unplanned revascularization, and persistent angina.
View Article and Find Full Text PDFJ Clin Lipidol
April 2009
Department of Medicine, Division of Cardiology, Health Sciences Center #T16 - 080, State University of New York, Stony Brook, NY 11794 USA.
Background: Both colesevelam hydrochloride (colesevelam) and ezetimibe monotherapy have been reported to lower low-density lipoprotein cholesterol (LDL-C) approximately 15-17% in patients with hypercholesterolemia. When statin therapy is inadequate to reach desired LDL-C goals, the choice of add-on therapy, while multifactorial, must consider efficacy of additional LDL-C reduction.
Objective: To provide pilot study data in assessing the relative potential of ezetimibe or colesevelam to further reduce LDL-C in statin-treated patients.
Circulation
February 2009
Electrophysiology Laboratories, Stony Brook University School of Medicine, Health Sciences Center T16-080, 100 Nicolls Rd, Stony Brook, NY 11794, USA.
Background: The Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP) tested the hypothesis that opening a persistently occluded infarct-related artery by percutaneous coronary intervention and stenting (PCI) after the acute phase of myocardial infarction compared with optimal medical therapy alone reduces markers of vulnerability to ventricular arrhythmias.
Methods And Results: Between April 2003 and December 2005, 300 patients with an occluded native infarct-related artery 3 to 28 days (median, 12 days) after myocardial infarction were randomized to PCI or optimal medical therapy. Ten-minute digital Holter recordings were obtained before randomization, at 30 days, and at 1 year.
Curr Treat Options Cardiovasc Med
October 2007
Stony Brook University Medical Center, Department of Medicine, Division of Cardiology, Health Sciences Center T16-080, Stony Brook, NY 11794, USA.
The results of the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial indicate that the rate control strategy is preferred for the majority of patients with paroxysmal and persistent atrial fibrillation (AF). If the patient remains symptomatic despite adequate rate control or if rate control cannot be achieved, then rhythm control therapies are indicated. The most likely explanation for the disappointing results of the AFFIRM trial is the poor efficacy and excessive toxicity of rhythm control medications, because the presence of sinus rhythm was associated with a favorable prognosis in AFFIRM.
View Article and Find Full Text PDF